ABO主要不相合血小板输注与脑出血后脑缺血相关
本研究纳入2009至2016年一家三级学术中心收治的40例脑出血后24小时内接受单份血小板输注、有供受体ABO数据且住院期间完成脑MRI的成人患者,用校正回归模型评估ABO主要不相合血小板与MRI缺血灶的关系。结果显示20%患者接受了ABO主要不相合血小板单位,校正脑出血严重程度后该暴露与MRI缺血灶风险升高相关(校正OR 9.2,95%CI 1.3-62.7)。作者认为这一探索性发现提示ABO主要不相合血小板输注可能参与脑出血后的继发性脑损伤。
要点
- 脑出血后接受ABO主要不相合血小板输注者,校正脑出血严重程度后MRI缺血灶风险升高(校正OR 9.2)。
- 该研究为探索性设计,样本仅40例,结论需进一步研究验证。
- 是否避免ABO主要不相合血小板输注可减少继发性脑损伤尚待评估。
核心结论
- 探索性发现提示ABO主要不相合血小板输注可能与脑出血后继发性脑损伤相关。
- 尚需进一步研究评估避免ABO主要不相合血小板输注能否预防继发性脑损伤并改善脑出血结局。
研究设计与样本
- 研究为回顾性分析,纳入2009至2016年一家三级学术中心收治的成人脑出血患者。
- 纳入标准为入院24小时内接受单份血小板输注、有供受体ABO数据且住院期间完成脑MRI,共40例。
- 采用校正回归模型评估ABO主要不相合血小板单位与MRI缺血灶的关系,校正因素包括脑出血严重程度。
主要发现
- 研究共纳入40例患者,平均年龄67.1岁(SD 14.1),女性占37.5%。
- 20%的患者接受了ABO主要不相合血小板单位。
- 校正脑出血严重程度后,ABO主要不相合血小板输注与MRI缺血灶风险升高相关(校正OR 9.2,95%CI 1.3-62.7)。
临床怎么用
- 对脑出血后需血小板输注的患者,ABO主要不相合输注可能是MRI缺血灶的危险信号,需关注继发性脑损伤。
- 当前证据仅为探索性,不宜据此直接改变输血策略,应结合个体情况权衡。
局限性
- 研究为单中心、小样本(40例)的探索性分析,结果需外部验证。
- 原文未报告其他局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major ABO-incompatible platelet transfusions are associated with poor intracerebral hemorrhage (ICH) outcomes, yet drivers for this relationship remain unclear. Brain magnetic resonance imaging (MRI) ischemic lesions after ICH are neuroimaging biomarkers of secondary brain injury and are associated with poor outcomes. Given that ABO-incompatible platelet transfusions can induce immune complex formation, thrombo-inflammation, and endothelial barrier disruption, factors that could exacerbate cerebral ischemia, we explored whether major ABO-incompatible platelet transfusions are risk factors for ischemic lesions on brain MRI after ICH. METHODS: Adult patients admitted to a tertiary-care academic center between 2009 and 2016 who received a single-platelet transfusion within 24 hours of admission after an ICH, had available donor/recipient ABO data, and brain MRI during the hospitalization were analyzed. Adjusted regression models evaluated relationships between major ABO-incompatible platelet units and MRI ischemic lesions. RESULTS: A total of 40 patients were included in the study. The mean age was 67.1 (SD, 14.1), and 37.5% were female. Twenty percent of patients received a major ABO-incompatible platelet unit. Major ABO-incompatible platelet transfusions were associated with increased odds of MRI ischemic lesions after adjusting for ICH severity (adjusted odds ratio, 9.2 [95% CI, 1.3-62.7]). CONCLUSIONS: Our exploratory findings suggest that major ABO-incompatible platelet transfusions may contribute to secondary brain injury after ICH. Further work is needed to assess whether avoiding major ABO-incompatible platelet transfusions can prevent secondary brain injury burden and improve ICH outcomes.
引用
- Carvalho Poyraz F, Ridha M, Simonetto M, et al. Major ABO-Incompatible Platelet Transfusions Are Associated With Brain Ischemia After Intracerebral Hemorrhage. Stroke. 2025. PMID: 40931826. doi:10.1161/STROKEAHA.125.051427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。